5,964 Shares in Celgene Co. (NASDAQ:CELG) Bought by Mint Tower Capital Management B.V.

Mint Tower Capital Management B.V. purchased a new stake in shares of Celgene Co. (NASDAQ:CELG) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,964 shares of the biopharmaceutical company’s stock, valued at approximately $563,000.

Several other institutional investors also recently bought and sold shares of CELG. Altium Wealth Management LLC increased its stake in Celgene by 1.3% in the first quarter. Altium Wealth Management LLC now owns 8,980 shares of the biopharmaceutical company’s stock valued at $847,000 after acquiring an additional 115 shares during the period. Global Retirement Partners LLC grew its stake in Celgene by 10.0% during the first quarter. Global Retirement Partners LLC now owns 1,269 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 115 shares during the last quarter. Community Bank N.A. grew its stake in Celgene by 3.2% during the first quarter. Community Bank N.A. now owns 3,922 shares of the biopharmaceutical company’s stock worth $370,000 after buying an additional 120 shares during the last quarter. Manchester Capital Management LLC grew its stake in Celgene by 1.2% during the first quarter. Manchester Capital Management LLC now owns 9,768 shares of the biopharmaceutical company’s stock worth $922,000 after buying an additional 120 shares during the last quarter. Finally, Iberiabank Corp grew its stake in Celgene by 1.0% during the first quarter. Iberiabank Corp now owns 12,019 shares of the biopharmaceutical company’s stock worth $1,134,000 after buying an additional 121 shares during the last quarter. Institutional investors and hedge funds own 75.01% of the company’s stock.

CELG has been the topic of several research analyst reports. Sanford C. Bernstein reaffirmed a “sell” rating on shares of easyJet in a research note on Monday, April 1st. Zacks Investment Research raised shares of IMI PLC/S from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd. Mizuho set a $148.00 price target on shares of Jazz Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, July 3rd. Cantor Fitzgerald set a $11.00 price objective on shares of TAIWAN LIPOSOME/S and gave the company a “buy” rating in a report on Friday, April 5th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Two research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $95.56.

CELG stock traded down $0.48 during midday trading on Friday, hitting $91.93. The company’s stock had a trading volume of 3,028,929 shares, compared to its average volume of 4,452,765. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $98.97. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.78 and a quick ratio of 2.66. The company has a market capitalization of $64.83 billion, a price-to-earnings ratio of 12.08, a price-to-earnings-growth ratio of 0.44 and a beta of 1.45. The business has a 50 day moving average price of $94.94.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.45 by $0.10. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The business had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.01 billion. During the same period in the prior year, the company posted $2.05 EPS. The firm’s revenue for the quarter was up 13.8% compared to the same quarter last year. On average, analysts expect that Celgene Co. will post 9.85 EPS for the current year.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Why do analysts give a neutral rating?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.